{
    "clinical_study": {
        "@rank": "6470", 
        "acronym": "PRESTOC2", 
        "arm_group": [
            {
                "arm_group_label": "Deep brain stimulation", 
                "arm_group_type": "Experimental", 
                "description": "Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.There are three stimulation phases (subthalamic nucleus, caudate nucleus and nucleus accumbens) to be tested."
            }, 
            {
                "arm_group_label": "no intervention", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Deep brain stimulation (DBS) has been proposed for severe and resistant obsessive-compulsive\n      disorder. This electrical stimulation has been tested on, and shown to be effective at,\n      different targets (subthalamic nucleus, caudate nucleus & nucleus accumbens). However, the\n      efficacies of each target have never been compared directly.\n\n      This protocol aims to do so, with the hypothesis that subthalamic (STN) stimulation will be\n      more efficacious."
        }, 
        "brief_title": "Comparison of DBS Targets in Obsessive-compulsive Disorder", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obsessive-Compulsive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Deep brain stimulation has been proposed for severe and resistant obsessive-compulsive\n      disorder (OCD). This electrical stimulation has been tested on, and shown to be effective\n      at, different targets (subthalamic nucleus, caudate nucleus & nucleus accumbens). However,\n      the efficacies of each target have never been compared directly.\n\n      Therefore, bilateral subthalamic and caudate electrodes will be implanted in severe OCD\n      patients. Efficacy of stimulation at the different targets will be assessed using a\n      double-blind randomised crossover design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Age 18 - 60\n\n          -  OCD according to DSM IV, at least 5 years since diagnosis\n\n          -  Severe OCD responsible for a clinically significant and objective alteration of\n             psychosocial functioning and suffering: YBOCS score>25, CGI score >= 4 and EGF score\n             <= 40\n\n          -  Resistance of OCD to at least 3 antidepressants from the serotonin reuptake\n             inhibitors category, including clomipramine, given for at least 12 weeks with doses\n             of at least 80mg/d for fluoxetine, 300mg/d for fluvoxamine, 200mg/d for sertraline,\n             60mg/d for paroxetine and citalopram, 250mg/d for clomipramine). Plus resistance to\n             each of these 3 antidepressant associated first to risperidone or pimozide for a\n             month then to Lithium carbonate, clonazepam, buspirone or pindolol for a month\n\n          -  Resistance to at least 2 behavioural and cognitive therapies conducted by as many\n             different specialists, following validated protocols (e.g. exposition and prevention\n             of response)\n\n          -  Oral and written knowledge of French\n\n          -  Social security coverage\n\n          -  Written consent of the patient after clear description of the study\n\n        Exclusion criteria :\n\n          -  cognitive alteration with PM38 score < IQ85\n\n          -  Other axis 1 disorder according to DSM IV, excepted, global anxiety disorder, social\n             phobia, nicotine dependance, and antecedent of major depressive episodes\n\n          -  suicidal risk >=2 on item 10 of MADRS (Montgomery Asberg Depression Rating Scale)\n\n          -  Personality disorder (axis 2 of DSM IV assessed using the SCID II)\n\n          -  Contra indication to MRI, abnormal brain MRI, other severe intercurrent disease\n\n          -  Fertile woman without adequate contraception\n\n          -  Pregnancy\n\n          -  Forced psychiatric hospitalisation\n\n          -  Any kind of legal protection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807403", 
            "org_study_id": "P081203"
        }, 
        "intervention": {
            "arm_group_label": "Deep brain stimulation", 
            "description": "Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.", 
            "intervention_name": "Deep brain stimulation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obsessive-Compulsive Disorder", 
            "Deep brain stimulation", 
            "Subthalamic nucleus", 
            "Caudate nucleus", 
            "Nucleus accumbens"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75013"
                }, 
                "name": "Centre d'investigation Clinique Piti\u00e9 Salp\u00eatri\u00e8re"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder.", 
        "overall_official": {
            "affiliation": "Assitance Publique - Hopitaux de Paris", 
            "last_name": "Luc Mallet, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Severity as measured by the Yale-Brown Obsession and Compulsion scale", 
            "measure": "Severity of symptoms after each phase", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Severity as measured by the Yale-Brown Obsession and Compulsion scale", 
                "measure": "Severity of symptoms after each phase", 
                "safety_issue": "No", 
                "time_frame": "month 0"
            }, 
            {
                "description": "Severity as measured by the Yale-Brown Obsession and Compulsion scale", 
                "measure": "Severity of symptoms after each phase", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Severity as measured by the Yale-Brown Obsession and Compulsion scale", 
                "measure": "Severity of symptoms after each phase", 
                "safety_issue": "No", 
                "time_frame": "10 months"
            }, 
            {
                "description": "Severity as measured by the Yale-Brown Obsession and Compulsion scale", 
                "measure": "Severity of symptoms after each phase", 
                "safety_issue": "No", 
                "time_frame": "14 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}